From Investorplace:
While the rally from biotech stocks feels like it’s getting a little long in the tooth, a closer inspection of these names reveals there’s plenty more to be excited about … long-term as well as short-term.
Depending on the company in question, FDA approvals may be around the corner, a swing to a profit may be in the cards, or maybe there’s just plenty of assurance that a drug still has several years of life — and growth — ahead of it.
In fact, while most of these stocks have been moving upward for a while, many of them also look like stocks to buy here and now, with the best yet to come.